🇫🇷 IPN.PA — Ipsen S.A.

Salud Mantener
← Volver

Precio actual

153,20 EUR

Máx. histórico

172,90

181 días

Caída desde máximo

-11,39%

Rango 52 semanas

115,60 – 174,00

Variación hoy

-1,42%

Cierre anterior

155,40

Rango de hoy

152,70 – 157,00

Volumen hoy

131.211

Peor caída histórica

-75,62%

30/08/2018 → 18/03/2020

Recuperado en 2157 días

Volatilidad anualizada ⓘ

30,51%

Información
Nombre completo
Ipsen S.A.
Divisa
EUR
Mercado
Paris
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
5.535
PER ⓘ
24,79 (puede no estar actualizado)
Dividend yield
1,03% (puede no estar actualizado)
Precio objetivo analistas
161,92 EUR (puede no estar actualizado)
Primera cotización
07/12/2005
Precio actualizado
hace 13 horas
Sobre la empresa

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Dividendos repartidos Total últimos 12 meses: 1,6000 EUR · Yield: 1,04%
Fecha de pago Importe por participación
03/06/2026 1,6000 EUR
04/06/2025 1,4000 EUR
30/05/2024 1,2000 EUR
02/06/2023 1,2000 EUR
31/05/2022 1,2000 EUR
31/05/2021 1,0000 EUR
03/06/2020 1,0000 EUR
31/05/2019 1,0000 EUR
04/06/2018 1,0000 EUR
09/06/2017 0,8500 EUR
02/06/2016 0,8500 EUR
29/05/2015 0,8500 EUR
09/06/2014 0,8000 EUR
05/06/2013 0,8000 EUR
06/06/2012 0,8000 EUR
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
31/08/2023 119,90 121,50 119,50 119,80 +0,00% 1,67% 182.517
30/08/2023 120,10 120,30 119,70 119,80 -0,33% 0,50% 33.011
29/08/2023 119,00 120,80 119,00 120,20 +1,09% 1,51% 36.898
28/08/2023 120,10 120,70 118,30 118,90 -0,17% 2,00% 42.139
25/08/2023 117,50 119,10 117,50 119,10 +1,10% 1,36% 65.472
24/08/2023 117,00 118,30 116,90 117,80 +0,94% 1,20% 48.807
23/08/2023 116,90 117,30 116,20 116,70 -0,09% 0,94% 55.248
22/08/2023 116,60 116,90 116,00 116,80 +0,95% 0,77% 72.370
21/08/2023 116,70 117,20 114,40 115,70 -0,34% 2,40% 87.481
18/08/2023 118,20 118,20 115,60 116,10 -1,69% 2,20% 81.058
17/08/2023 122,00 122,00 118,10 118,10 -2,72% 3,20% 98.990
16/08/2023 122,20 123,10 121,40 121,40 -0,90% 1,39% 67.266
15/08/2023 121,90 122,50 121,10 122,50 +0,66% 1,15% 48.355
14/08/2023 121,00 122,60 121,00 121,70 +0,50% 1,32% 56.250
11/08/2023 121,40 122,20 120,70 121,10 -0,66% 1,24% 55.486
10/08/2023 121,00 122,20 120,90 121,90 +0,99% 1,07% 52.658
09/08/2023 121,40 121,80 120,00 120,70 +0,08% 1,48% 49.474
08/08/2023 116,40 121,40 116,20 120,60 +4,24% 4,47% 91.847
07/08/2023 114,70 116,10 113,90 115,70 +0,61% 1,92% 50.896
04/08/2023 114,20 115,70 113,70 115,00 +0,52% 1,75% 67.235
03/08/2023 114,10 114,50 111,70 114,40 -0,09% 2,45% 74.877
02/08/2023 115,30 115,30 113,70 114,50 -1,29% 1,39% 67.624
01/08/2023 114,90 117,40 114,50 116,00 +1,22% 2,52% 65.234
31/07/2023 114,50 115,50 112,50 114,60 -0,43% 2,62% 78.264
28/07/2023 113,50 115,90 113,50 115,10 +1,77% 2,11% 66.742
27/07/2023 110,40 115,00 110,40 113,10 +2,72% 4,17% 76.415
26/07/2023 110,10 110,60 109,60 110,10 -0,18% 0,91% 33.841
25/07/2023 111,30 111,40 109,80 110,30 -0,99% 1,44% 52.253
24/07/2023 110,90 111,80 110,60 111,40 +0,36% 1,08% 44.426
21/07/2023 112,40 112,70 110,40 111,00 -1,25% 2,05% 73.508